drugset / Press release
Ultragenyx Initiates New Development Program Studying Triheptanoin (UX007) for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
2013-08-05 · Ultragenyx Pharmaceutical Inc · original ultragenyx.com ↗
Ultragenyx Initiates New Development Program Studying Triheptanoin (UX007) for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
The release as fetched from its publisher. ultragenyx.com ↗